Skip to main content
Top
Published in: European Journal of Plastic Surgery 2/2006

01-08-2006 | Case Report

The longest known interval between commencement of intravenous infusion of gabexate mesilate and the development of a hand cyst

Authors: H. Iioka, M. Hatoko, M. Kuwahara, S. Yurugi, K. Niitsuma

Published in: European Journal of Plastic Surgery | Issue 2/2006

Login to get access

Abstract

A 4-year-old Japanese girl received a continuous infusion of gabexate mesilate (200 mg/25 ml 5% glucose) for 6 days via a peripheral vein for the treatment of hemolytic uremic syndrome. After administration, pigmentation was seen at the needle entry point on her right hand. Six years later, an elastic, hard subcutaneous mass was noted around this pigmentation. The tumor was encapsulated and partially adherent to the tendon of the extensor digitorum muscle. Histological examination revealed a membranous structure consisting of fibrous tissue containing many inflammatory cells. This was considered to be a side effect of gabexate mesilate.
Literature
1.
go back to reference Comas D, Mateu J (1996) Treatment of extravasation of both doxyrubicin and vincristine administration in a Y-site infusion. Ann Pharmacother 30:244–246PubMed Comas D, Mateu J (1996) Treatment of extravasation of both doxyrubicin and vincristine administration in a Y-site infusion. Ann Pharmacother 30:244–246PubMed
2.
go back to reference Harada K, Kawamura T, Yamada K et al (1996) Skin damage induced by gabexate mesilate (FOY). Rinsho Derma (Tokyo) 38:1777–1780 Harada K, Kawamura T, Yamada K et al (1996) Skin damage induced by gabexate mesilate (FOY). Rinsho Derma (Tokyo) 38:1777–1780
3.
go back to reference Kumon K, Tanaka K, Kishimoto Y, et al (1982) The result of gabexate mesilate (FOY) administration for the disseminated intravascular coagulation (DIC) seen after open heart surgery. ICU to CCU 6:473–479 Kumon K, Tanaka K, Kishimoto Y, et al (1982) The result of gabexate mesilate (FOY) administration for the disseminated intravascular coagulation (DIC) seen after open heart surgery. ICU to CCU 6:473–479
4.
go back to reference Matsuoka Y, Mori T, Yamamoto Y et al (1978) Toxicities and teratogenicity of (ethyl p-(6-guanidinohexanoyloxy) benzoate) methanesulfonate (FOY). Ouyouyakuri 15:53–84 Matsuoka Y, Mori T, Yamamoto Y et al (1978) Toxicities and teratogenicity of (ethyl p-(6-guanidinohexanoyloxy) benzoate) methanesulfonate (FOY). Ouyouyakuri 15:53–84
5.
go back to reference Ohara S, Motrioka S, Nakakita T (1995) Skin ulcer due to gabexate mesilate (FOY). Rinsho Derma (Tokyo) 37:459–461 Ohara S, Motrioka S, Nakakita T (1995) Skin ulcer due to gabexate mesilate (FOY). Rinsho Derma (Tokyo) 37:459–461
6.
go back to reference Shigera K, Miyashita K, Sugamata A (2002) A case of subcutaneous cysts of bilateral arm due to administration of gabexate mesilate in later. J Jpn Plast Reconstr Surg 22:319–324 Shigera K, Miyashita K, Sugamata A (2002) A case of subcutaneous cysts of bilateral arm due to administration of gabexate mesilate in later. J Jpn Plast Reconstr Surg 22:319–324
7.
go back to reference Yuasa T, Taniguchi Y, Yamada E et al (1997) Severe cutaneous and venous damage after DIC therapy. J Dermatol 24:466–470PubMed Yuasa T, Taniguchi Y, Yamada E et al (1997) Severe cutaneous and venous damage after DIC therapy. J Dermatol 24:466–470PubMed
Metadata
Title
The longest known interval between commencement of intravenous infusion of gabexate mesilate and the development of a hand cyst
Authors
H. Iioka
M. Hatoko
M. Kuwahara
S. Yurugi
K. Niitsuma
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
European Journal of Plastic Surgery / Issue 2/2006
Print ISSN: 0930-343X
Electronic ISSN: 1435-0130
DOI
https://doi.org/10.1007/s00238-006-0046-1

Other articles of this Issue 2/2006

European Journal of Plastic Surgery 2/2006 Go to the issue

Letter to the Editor

A letter from Malawi